Strategic Integration: Viant + Electrome + BIEL =
Post# of 8742
(Total Views: 97)
Posted On: 10/21/2025 3:49:24 PM
Strategic Integration: Viant + Electrome + BIEL = Scalable Innovation & Financial Upside
Viant Medical and Electrome stand to gain significantly by deepening their involvement with BIEL—not just through partnerships, but by acquiring equity or outright shares. With BIEL on the cusp of profitability and holding valuable IP, the upside is both technological and financial.
Why Viant & Electrome Should Take a Stake in BIEL
Immediate Access to FDA-Cleared Tech BIEL’s ActiPatch and RecoveryRx are already FDA-cleared and clinically validated, reducing regulatory risk and accelerating go-to-market timelines.
Ultra-Low Operating Costs BIEL’s lean model means even modest revenue growth unlocks profitability—ideal for investors seeking high-margin returns.
Tax-Free Profit Potential BIEL holds a $40M tax-loss carryforward, allowing the first $40M in profits to be tax-free—preserving cash flow and boosting ROI.
Undervalued Share Price With PPS near historical lows, even modest growth could yield exponential returns. Strategic investment now could yield:
3,000% gain at $0.003 PPS*
200,000% gain at $0.02 PPS*
400,000% gain at $0.04 PPS*
$1 PPS possible post-debt payoff and stock buyback
*ballpark estimates dependent on PPS purchase price
Veterinary Market Goldmine RecoveryRx outperforms competitors like Assisi Loop and opens a new revenue stream in pet wellness and pain management.
DARPA Alignment BIEL’s tech aligns with DARPA’s BEST and BETR programs—positioning it for federal funding and defense applications.
Partnership Structures That Support Investment
Technology Licensing Agreement, BIEL licenses PSWT tech to Electrome
Viant ensures regulatory alignment, Electrome monetizes without reinventing the wheel
Joint Device Development, Co-create next-gen neuromodulation devices, Target chronic pain, post-op recovery, mental health
Viant leads clinical trial design and FDA strategy, Contract Manufacturing & Scale-Up
Viant manufactures BIEL’s devices, Rapid scale-up with existing infrastructure, Koneru ensures CE/FDA compliance
Clinical Research Collaboration, Electrome + BIEL co-sponsor trials, explore new PSWT applications
Viant supports protocol design and publication
Strategic Investment or Acquisition:
Electrome or Viant acquire equity in BIEL
Consolidate IP, talent, and distribution
Koneru bridges leadership and technical teams
White-Labeling / OEM Partnership
Electrome rebrands BIEL’s devices for niche markets
Viant customizes specs and ensures branding compliance
BIEL’s Fast Path to Profitability
$400K Quarterly Revenue, unlocks profitability and cash flow positivity, drives PPS toward copper levels
$1.5M Annual Revenue, confirms sustainable growth, strengthens investor confidence
Electrome as US Distributor - If partnership valued at $300K–$1M, PPS moves out of the trips, likely into copper
Veterans Administration Approval:
RecoveryRx validated for phantom limb pain
Opens doors to broader federal adoption
Strategic Summary
By acquiring shares in BIEL, Viant and Electrome gain:
A stake in a clinically validated, FDA-cleared product portfolio
Entry into high-growth human and veterinary wellness markets
Tax-advantaged profit potential
A scalable platform for bioelectronic innovation
Sree Koneru, with his dual role at Viant and BIEL, is the linchpin—aligning engineering, regulatory, and strategic execution across all three entities.
Viant Medical and Electrome stand to gain significantly by deepening their involvement with BIEL—not just through partnerships, but by acquiring equity or outright shares. With BIEL on the cusp of profitability and holding valuable IP, the upside is both technological and financial.
Why Viant & Electrome Should Take a Stake in BIEL
Immediate Access to FDA-Cleared Tech BIEL’s ActiPatch and RecoveryRx are already FDA-cleared and clinically validated, reducing regulatory risk and accelerating go-to-market timelines.
Ultra-Low Operating Costs BIEL’s lean model means even modest revenue growth unlocks profitability—ideal for investors seeking high-margin returns.
Tax-Free Profit Potential BIEL holds a $40M tax-loss carryforward, allowing the first $40M in profits to be tax-free—preserving cash flow and boosting ROI.
Undervalued Share Price With PPS near historical lows, even modest growth could yield exponential returns. Strategic investment now could yield:
3,000% gain at $0.003 PPS*
200,000% gain at $0.02 PPS*
400,000% gain at $0.04 PPS*
$1 PPS possible post-debt payoff and stock buyback
*ballpark estimates dependent on PPS purchase price
Veterinary Market Goldmine RecoveryRx outperforms competitors like Assisi Loop and opens a new revenue stream in pet wellness and pain management.
DARPA Alignment BIEL’s tech aligns with DARPA’s BEST and BETR programs—positioning it for federal funding and defense applications.
Partnership Structures That Support Investment
Technology Licensing Agreement, BIEL licenses PSWT tech to Electrome
Viant ensures regulatory alignment, Electrome monetizes without reinventing the wheel
Joint Device Development, Co-create next-gen neuromodulation devices, Target chronic pain, post-op recovery, mental health
Viant leads clinical trial design and FDA strategy, Contract Manufacturing & Scale-Up
Viant manufactures BIEL’s devices, Rapid scale-up with existing infrastructure, Koneru ensures CE/FDA compliance
Clinical Research Collaboration, Electrome + BIEL co-sponsor trials, explore new PSWT applications
Viant supports protocol design and publication
Strategic Investment or Acquisition:
Electrome or Viant acquire equity in BIEL
Consolidate IP, talent, and distribution
Koneru bridges leadership and technical teams
White-Labeling / OEM Partnership
Electrome rebrands BIEL’s devices for niche markets
Viant customizes specs and ensures branding compliance
BIEL’s Fast Path to Profitability
$400K Quarterly Revenue, unlocks profitability and cash flow positivity, drives PPS toward copper levels
$1.5M Annual Revenue, confirms sustainable growth, strengthens investor confidence
Electrome as US Distributor - If partnership valued at $300K–$1M, PPS moves out of the trips, likely into copper
Veterans Administration Approval:
RecoveryRx validated for phantom limb pain
Opens doors to broader federal adoption
Strategic Summary
By acquiring shares in BIEL, Viant and Electrome gain:
A stake in a clinically validated, FDA-cleared product portfolio
Entry into high-growth human and veterinary wellness markets
Tax-advantaged profit potential
A scalable platform for bioelectronic innovation
Sree Koneru, with his dual role at Viant and BIEL, is the linchpin—aligning engineering, regulatory, and strategic execution across all three entities.
(2)
(0)